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Development of the Standards of Reporting of
Neurological Disorders (STROND) checklist
A guideline for the reporting of incidence and prevalence studies in
neuroepidemiology
ABSTRACT
Background: Incidence and prevalence studies of neurologic disorders play an important role in
assessing the burden of disease and planning services. However, the assessment of disease es-
timates is hindered by problems in reporting for such studies. Despite a growth in published re-
ports, existing guidelines relate to analytical rather than descriptive epidemiologic studies.
There are also no user-friendly tools (e.g., checklists) available for authors, editors, and peer re-
viewers to facilitate best practice in reporting of descriptive epidemiologic studies for most neu-
rologic disorders.
Objective: The Standards of Reporting of Neurological Disorders (STROND) is a guideline that
consists of recommendations and a checklist to facilitate better reporting of published incidence
and prevalence studies of neurologic disorders.
Methods: A review of previously developed guidance was used to produce a list of items required
for incidence and prevalence studies in neurology. A 3-round Delphi technique was used to iden-
tify the “basic minimum items” important for reporting, as well as some additional “ideal reporting
items.” An e-consultation process was then used in order to gauge opinion by external neuro-
epidemiologic experts on the appropriateness of the items included in the checklist.
Findings: Of 38 candidate items, 15 items and accompanying recommendations were developed
along with a user-friendly checklist.
Conclusions: The introduction and use of the STROND checklist should lead to more consistent,
transparent, and contextualized reporting of descriptive neuroepidemiologic studies resulting in
more applicable and comparable findings and ultimately support better health care decisions.
Neurology® 2015;85:821–828
GLOSSARY
GBD 5 Global Burden of Disease and Injuries; HIC 5 high-income countries; LMIC 5 low- to middle-income countries; PD 5
Parkinson disease; STROBE 5 Strengthening the Reporting of Observational Studies in Epidemiology; STROND 5 Stand-
ards of Reporting of Neurological Disorders.
Neurologic diseases are becoming more prevalent as
the world’s population ages and their burden is
expected to increase globally.1 These conditions are
often subtle in their clinical manifestation and are
prone to misconceptions and misinterpretations.2 In
epidemiologic studies, neurologic conditions can pro-
vide particular challenges including: (1) the diagnos-
tic criteria tend to be variable, or subjective, or prone
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to misclassification; (2) the diagnosis of the condition
is based on the clinical phenotype but also on data
that may require the use of sophisticated technology
such as MRI or measuring biomarkers from plasma
and CSF; this may require both access to such equip-
ment and specialist skills in order to accurately deter-
mine whether an individual is a case (and it is subject
to a certain degree of operator-dependent error); (3)
there can be considerable heterogeneity in latency
periods resulting in variable and long gaps between
disease onset and manifestation of symptoms; (4)
pathologic confirmation in vivo may be difficult or
unavailable for certain neurologic conditions; and (5)
many neurologic conditions are rare.
High-quality prevalence and incidence studies
of neurologic conditions that follow a systematic
approach are essential for estimating the burden of dis-
ease globally, for comparison of estimates between var-
ious countries and populations, for priority setting,
resource allocation, and planning public health
approaches. For neurologic conditions, descriptive epi-
demiologic studies can provide important information
on (1) trends and gaps in the health service needs; (2)
estimates of morbidity, mortality, and economic bur-
den from these diseases; and (3) can be used for gener-
ating new hypotheses on causation or natural history of
the disease. Descriptive epidemiologic studies are par-
ticularly useful for estimating prevalence, incidence,
and morbidity and mortality time trends for studies
where global health is of concern.3 For instance, there
is usually more information available for high-income
countries (HIC), but for low- to middle-income coun-
tries (LMIC), the number of descriptive epidemiologic
studies conducted is sparse. However, studies from
both HIC and LMIC can be of poor quality because
of poor reporting, poor methodology, or both.4,5 It is
becoming increasingly important to collect high-
quality routine information on neurologic disorders
from LMIC in addition to those from HIC because
these populations are likely to be the ones where the
greatest future need for health services and treatment
will be required by the middle of this century.6
Any approach to attempt to bridge the gap world-
wide would require methods or guidelines that reduce
inconsistencies in reporting that may identify health
disparities between resource-rich and resource-poor re-
gions that are disseminated widely.7,8 Good reporting
strategies for neuroepidemiologic studies can be used
to facilitate meta-analyses and systematic reviews, and
are therefore of critical importance. General quality
checklists and reporting standards are common for par-
ticular types of studies (and, increasingly, expected) in
health services research; see, for example, CONSORT
for randomized controlled trials,9 PRISMA for system-
atic reviews,10 and SQUIRE for quality-improvement
studies.11 They have 2 main purposes: to help
researchers design, undertake, and report robust stud-
ies, and to help reviewers and potential users of
research outputs assess risk of bias (in terms of validity
and reliability). The Strengthening the Reporting of
Observational Studies in Epidemiology (STROBE)
guidelines12 are well known and widely used but were
devised for analytical epidemiology (i.e., case-control
studies, cohort studies, and cross-sectional studies).
We aim to develop a reporting guideline that out-
lines the key information to be reported for descrip-
tive health policy research (such as Global Burden
of Disease and Injuries [GBD]-type studies),13 as
studies that are not necessarily obviously
population-based, particularly those from settings
where there are few data, might be of greater value
to projects such as the GBD that need to synthesize
evidence, if they were reported better. For example, a
systematic review of incidence and prevalence of mul-
tiple sclerosis across the Americas found that there
were inconsistencies in methodologies and reporting
quality among the published studies.14 A review of
dementia in Parkinson disease (PD) found that PD
and the prevalence rates of dementia were usually
reported in the different age groups, and age-
specific prevalence rates of dementia in PD were usu-
ally not reported, which made comparisons between
studies infeasible.15 Another review of the most pop-
ulous countries found that it was not possible to make
a distinction between burden based on the absolute
number of cases of PD and burden based on the rel-
ative mix of severity of disease as this was poorly
reported.16 The recent GBD 2013 report on all-
cause and cause-specific mortality noted that the es-
timates of Alzheimer disease would be improved by
more population-based prevalence studies that use
and report standardized definitions and methods.17
The primary objective was to develop reporting guid-
ance for incidence and prevalence studies specifically
related to neurologic disorders using a consensus-
based process, but this information may also be of
interest to a general epidemiologic audience.
METHODS We followed the Guidance for Developers of
Health Research Reporting Guidelines18 and developed a 3-phase
consensus process (figure).
Phase I. The process consisted of empirical work, split into 4 dif-
ferent components: (1) a systematic review of reporting guidelines
for incidence and prevalence studies in general and reporting
guidelines specific to a common neurologic condition (we used
stroke as an example for our initial investigations); (2) production
of a core set of important items for the reporting of incidence and
prevalence studies based on the review of the evidence; (3) assess
the quality of reporting of a random sample of published inci-
dence and prevalence studies of the common neurologic condi-
tion (stroke); and (4) proposed an initial checklist of a “core
set of items” that were then discussed with members of the
Standards of Reporting of Neurological Disorders (STROND)
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collaborative group. Appendix e-1 (on the Neurology® Web site
at Neurology.org) summarizes the results of phase I of the
development of the STROND guideline.
Phase II. A 3-round Delphi process was conducted using a
group of individuals who had expertise in neuroepidemiologic
research (who were not members of the STROND group) and
agreed to take part in a series of 3 consecutive rounds of
questionnaires designed to achieve increasing consensus of
opinion on which items should be included in the checklist.19
The Delphi process participants were identified by contacting
members of neurologic societies via e-mail. An online
questionnaire (that included tick boxes and free text comments)
was devised based on the relevant version of the questionnaire
(and took no more than 15 minutes to complete). This
questionnaire was circulated to participants who had agreed to
take part in each of the 3 rounds of the Delphi process.
Participants remained anonymous, which enabled them to
comment freely, but they were required to give their initials
and a memorable date when completing the questionnaire for
tracking purposes. Respondents were asked to suggest
additional items, that they believed were important, that were
missing from the initial checklist. After each round, the results
were summarized (both quantitative and free text information
was summarized) and fed back to the respondents along with
the updated version of the checklist that had been revised in
the light of the comments received.
Figure Structure of the guideline development process
STROND 5 Standards of Reporting of Neurological Disorders.
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Phase III. Once consensus had been reached on the items to be
included in the checklist based on phase I and II findings, then a
group of internationally recognized experts on neurologic disor-
ders (as nominated by members of the STROND collaborative
group) were contacted as part of a further e-consultation process
in order to assess their views (or “pilot”) on the contents of the
checklist. Once this 3-phase consensus process was completed, a
“final checklist” was produced based on the feedback received
from all the individuals who had participated.
RESULTS The initial checklist based on a systematic
review of the evidence yielded 27 items that were used
as part of the first round of the Delphi exercise.
Another 11 items that were not included in the initial
checklist were included based on feedback from the
first round. Table 1 gives details of the background
of the participants in the Delphi and the e-consultation
processes. Seventy-nine individuals participated in
the first round of the Delphi process and described
their area of expertise as clinical (80%), research
(77%), policy (10%), or methodologic (20%)
(Delphi process respondents were allowed to check
more than one general area of expertise in the online
questionnaire). The 79 individuals were from a
variety of countries and with contributions from
respondents based in high-income (52%), middle-
income (30%), and low-income (18%) countries.
Of the 79 individuals who completed the first
round, 65 individuals took part in the second
round (82%) and 61 took part in the third and
final round (77%). Consensus was deemed to be
reached when $70% of the respondents were in
agreement about the utility of a particular checklist
item in each successive round of the Delphi process.
The e-consultation process invited 30 individuals
who were prominent researchers, policymakers, or
methodologists in the field of neuroepidemiology.
Of the 30 invited individuals, 18 (60%) agreed to
participate in the e-consultation/piloting process.
The responses received from the e-consultation/
piloting process were then used to construct the
STROND guideline checklist, which is provided in
table 2. The checklist was structured to correspond
to key components that should be reported in the
final manuscript in a similar manner to the
STROBE checklist.12 The checklist has 15 key items
and distinguishes between items that are deemed to
be “basic minimum reporting” requirements (items
in nonitalic font), and items that are deemed to be
“ideal reporting” requirements (items in italic font).
For example, the item on the source population
(item 6) used in the study has 3 basic minimum
reporting requirements: using several different
sources for case identification; the core data used
to identify individuals (e.g., medical records, admin-
istrative databases); and a description of dropouts or
exclusions from the source population. The ideal
reporting requirements would also have details on
the rate of admission for the neurologic condition
in the population, details of the health care system in
the country where the study was conducted, and
details of filters on how the person with the neuro-
logic condition is referred. The checklist also dis-
tinguishes between items that relate specifically
to incidence or prevalence studies of neurologic
disorders.
DISCUSSION We envisage that the STROND
checklist will only be used to assess the reporting of
prevalence and incidence studies of neurologic disor-
ders. Although this checklist is aimed at reporting of
descriptive epidemiologic studies of neurologic disor-
ders, we believe that it would also be of interest to re-
searchers wishing to report their descriptive
epidemiologic studies of nonneurologic disorders.
The 15-item checklist provides a framework to satisfy
the need for completeness and transparency of report-
ing of incidence and prevalence studies of neurologic
disorders. We attempted to strike a balance between
adequate detail and concise reporting so we incorpo-
rate both “basic minimum reporting” standards as
well as “ideal reporting” criteria in the checklist.
There is substantial evidence that reporting guidelines
improve the completeness of published reports based
on natural experiments.20,21 As has been done with
other reporting guidelines,22 we aim to develop a
more detailed explanation and elaboration report that
provides more detail on the rationale for each item
included in the checklist and provides some empirical
evidence of good reporting of incidence and preva-
lence studies for neurologic disorders. The prelimi-
nary aims and objectives of the guideline have
been posted on the EQUATOR (Enhancing the Qual-
ity and Transparency of Health Research) Network23,24
and we plan to post the checklist and the explanation
and elaboration report on the EQUATOR Web site
(http://www.equator-network.org).
The limitations of this project are that the
STROND reporting guideline was developed using













Clinical 63 (80) 51 (80) 50 (82) 10 (55)
Research 61 (77) 45 (70) 44 (72) 16 (89)
Policy 8 (10) 6 (9) 7 (11) 2 (11)
Methodology 16 (20) 18 (28) 15 (24) 6 (33)
Data are n (%).
a Respondents were allowed to identify more than one area of expertise.
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Table 2 Standards of Reporting of Neurological Disorders (STROND): A guideline for the reporting of
incidence and prevalence studies in neuroepidemiology
Section/topic No. Recommendation
Title & abstract
Title and abstract 1 (a) Give the type of study design employed using a widely recognized
term in the title or abstract
(b) The abstract should give an accurate summary of how the study was
conducted and the main findings
Introduction
Background 2 Details of the scientific rationale for the study should be reported
Aims and objectives 3 State the specific aims and objectives of the study
Methods
Study design 4 Give a full description of the study design
4a Give details of any study protocol (published or unpublished that gives
additional useful information on the study design)
4b If a pilot study has been conducted to inform the main study design,
then the findings should be referenced
Setting 5 Clearly defined (usually, but not always, on a geographic basis), and
stable, with reliable information on in- and out-migration
Source population 6 Description of how all eligible members of the population were
identified and through what data sources (e.g., hospitals, outpatient
clinics, death certificates)
6a Source of data used for the study (e.g., administrative database,
medical records). If administrative database used, algorithms for data
extraction should be described
6b Description of the rate of hospital admission (if applicable) for the
neurologic condition in the population
6c Details of health care system in the country (study region) where the
study was conducted (e.g., public vs private health care system)
6d Description of how a person with the neurologic condition is referred
(with the filters) in the country (study region) where the study was
conducted
6e Description and characteristics of response rate/dropouts and
exclusion rate if applicable
Participants 7 Definition of cases is clearly identified and presented in sufficient detail
7a Details of the sampling method are described (are participants
representative of the source population?)
7b Fully validated source of diagnosis or “reference-standard” criteria
applied
7c Definition and justification of the disease severity (preferably using a
standardized severity scale) or staging of the disease
7d Description of how types/subtypes of the neurologic disorder of
interest are distinguished (if relevant)
7e Description of how completeness of case ascertainment was assessed
7f Description of whether completeness of case ascertainment was
adequate
Ethical approval 8 Details of ethics approval/informed consent/data governance should
be reported
Measurement 9a Incidence studies
Give details of how incidence was determined (based on timing of
data collection either prospectively or retrospectively)
Definition and justification of timing of measurements
The data presented to some specified time period (usually whole
years or person-time)
Raw numbers are reported in sufficient detail to calculate the
appropriate rates (e.g., by age or sex)
9b Prevalence studies
Give details of specific time points over which estimates are derived
(usually defined as the number of cases existing in a specific time
point)
Continued
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a consensus process and thus may only represent the
opinions of the participants. However, consensus
was reached on both the “basic minimum reporting”
standards and the “ideal reporting standards”
with .70% of respondents in agreement on the
items included in successive rounds of the Delphi
exercise. Furthermore, the independent group of ex-
perts who participated in the e-consultation were all
in broad agreement about the items included. In
addition, the Delphi technique has been used widely
in medical research as a survey method to gain
consensus among a group of respondents.25 For
example, a Delphi exercise process was employed by
the Consolidated Standards of Reporting Trials
(CONSORT) investigators when developing this
widely used reporting guideline.22
Large-scale projects like the GBD Study26 need to
utilize prevalence and incidence studies that use con-
sistent methods and terminology and also require
high-quality reporting in order to provide the
required information for their disease-modeling algo-
rithms to adequately estimate disease burden due to
these disorders. It is well known that rigorous
population-based studies from LMIC are sparse for
neurologic disorders (even for stroke), and the quality
of reporting in LMIC as well as HIC is in need of
improving.13 We will aim to translate the checklist
into languages other than English as required as well
Table 2 Continued
Section/topic No. Recommendation
The data presented to some specified time period (usually whole
years)
Raw numbers are reported in sufficient detail to calculate the
appropriate rates (e.g., by age or sex)
9c If disease burden is to be assessed, the study should report details of
burden due to a variety of sources (e.g., disability, disability-adjusted
life years, symptoms, financial, caregiver)
9d Report any arrangements for quality checks/data verification/
triangulation
9e Report details of the training of the person administering the
instruments
Statistical methods 10 If rates have been standardized (e.g., by age or sex), then the details of
the standard population used should be given
10a If possible, 2 standard populations should be used, one with local
relevance and the other to facilitate international comparisons
10b Description of any assumptions made in the calculations should be
reported
10c An explanation of how missing data were addressed in the analyses
10d Provide a priori estimates of sample size/power assessment/precision
of estimates assessment
10e Description of any sensitivity analyses
Results
Main findings 11 Consider a flow diagram that describes how participants were included
in the study (useful in order to assess how a person with the neurologic
condition of interest is referred [with the filters])
11a Give appropriate rates with their associated 95% confidence intervals
11b Report results of any sensitivity analyses
Discussion
Key findings 12 Summarize the key findings in relation to the study aims and objectives
Limitations 13 Discuss potential limitations of the study
13a Include details of risk of bias (e.g., selection bias), completeness of case
ascertainment, and data quality (assessment of its probability, size,
and potential importance)
Interpretation 14 Interpret the results in the context of the evidence from other well-
performed studies with similar designs and objectives
14a Reliability of the estimates (i.e., based on the reporting of the statistical
methodology, and study design, measurement of key information)
Generalizability 15 Discuss the external validity of the study findings
15a Are the results consistent with meta-analyses of descriptive
epidemiologic studies on the same topic that cover different settings (if
applicable)?
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as aiming to conduct and support research that inves-
tigates the impact of the guidelines on the reporting
quality of incidence and prevalence studies in neuro-
logic disorders.7 We hope that the introduction and
use of the STROND checklist will lead to more con-
sistent, transparent, and contextualized reporting of
population-based prevalence and incidence studies of
neurologic disorders and that these more applicable
findings will lead ultimately to better health care
decisions.
APPENDIX
Core Standard of Reporting of Neurological Disorders (STROND)
development team. Dr. Derrick Bennett (Nuffield Department of Pop-
ulation Health, University of Oxford, UK); Professor Carol Brayne
(Department of Public Health and Primary Care, University of
Cambridge, UK); Professor Valery Feigin (National Institute for Stroke
and Applied Neurosciences, AUT University, Auckland, New Zealand);
Helen McDonald (National Institute for Stroke and Applied Neurosci-
ences, AUT University, Auckland, New Zealand).
Standard of Reporting of Neurological Disorders (STROND) collabo-
rators. Professor Michael Brainin (Department for Clinical Medicine
and Preventive Medicine, Danube-University Krems, Austria); Profes-
sor Pierre-Marie Preux (Institute of Tropical Neurology, University of
Limoges, France); Professor Peter Rothwell (Stroke Prevention Unit,
University of Oxford, UK); Dr. Pablo M. Lavados (Vascular Neurology
and Stroke Unit, Neurology Service, Department of Medicine, Clínica
Alemana de Santiago, Universidad del Desarrollo and Department of
Neurological Sciences, Universidad de Chile, Institute of Neurosur-
gery, Santiago, Chile); Emeritus Professor John F. Kurtzke (George-
town University USA); Dr. Suzanne Barker-Collo (Department of
Psychology, University of Auckland, New Zealand); Dr. Daniel Davis
(Faculty of Population Health Sciences, University College London,
UK); Dr. Valentina Gallo (Centre of Primary Care and Public Health,
Blizard Institute, Queen Mary, University of London, UK);
Dr. Nathalie Jetté (Department of Clinical Neurosciences and Hotch-
kiss Brain Institute, Department of Community Health Sciences and
O’Brien Institute for Public Health, University of Calgary, Canada);
André Karch (Research Group Epidemiology and Statistical Methods,
Helmholtz Centre for Infection Research); Lawrence W. Svenson
(School of Public Health, University of Alberta, Canada); Professor
Giancarlo Logroscino (Neurodegenerative Diseases Unit, Department
of Basic Medicine, Neurosciences and Sense Organs, and Department
of Clinical Research in Neurology presso Fondazione Card Panico,
Tricase, University Aldo Moro, Bari, Italy); Gabriele Nagel (Institute
of Epidemiology and Medical Biometry, University of Ulm, Germany).
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